Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis

This study has been completed.
Sponsor:
Collaborator:
European Commission
Information provided by (Responsible Party):
Chiesi Farmaceutici S.p.A. ( Zymenex A/S )
ClinicalTrials.gov Identifier:
NCT01681953
First received: August 22, 2012
Last updated: September 1, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2014
  Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):